We can’t show the full text here under this license. Use the link below to read it at the source.
A prospective multicentre double-blind randomized controlled trial evaluating clinical, cognitive and neural effects of potentiation of electroconvulsive therapy by repetitive transcranial magnetic stimulation in patients with treatment-resistant depression (STIMAGNECT 2)
Clinical, thinking, and brain effects of adding repetitive magnetic stimulation to electroconvulsive therapy in hard-to-treat depression: a blinded, multi-center trial
AI simplified
Abstract
Eighty patients with will be evaluated in a trial assessing the impact of on outcomes.
- Approximately one-third of patients with major depressive disorder experience treatment-resistant depression, contributing to higher morbidity and healthcare costs.
- Electroconvulsive therapy is a key treatment for treatment-resistant depression but has limitations, including cognitive side effects and delayed symptom relief.
- Repetitive transcranial magnetic stimulation may enhance the efficacy of electroconvulsive therapy based on previous trials.
- The primary outcome measures the response rate after 10 ECT sessions, defined as a ≥ 50% reduction in Hamilton Depression Rating Scale scores.
- Secondary outcomes include assessments of depression severity, cognitive function, and potential changes in brain structure and connectivity.
AI simplified
Key numbers
≥ 50%
Response Rate
Defined as the proportion of patients achieving a reduction in HAMD scores after 10 sessions.
80 patients
Patient Enrollment
Total number of patients to be enrolled in the trial.